Rituximab exerts its anti-arthritic effects via inhibiting NF-κB/GM-CSF/iNOS signaling in B cells in a mouse model of collagen-induced arthritis

[1]  A. Nadeem,et al.  Treatment with the anti-CD20 monoclonal antibody rituximab mitigates gonadal disruptions in the collagen-induced arthritis in male DBA/1 J mouse model. , 2022, Mutation research.

[2]  M. A. Rosillo,et al.  A New Peracetylated Oleuropein Derivative Ameliorates Joint Inflammation and Destruction in a Murine Collagen-Induced Arthritis Model via Activation of the Nrf-2/Ho-1 Antioxidant Pathway and Suppression of MAPKs and NF-κB Activation , 2021, Nutrients.

[3]  Ju-Hee Lee,et al.  Polyherbal formula SC-E3 inhibits rheumatoid arthritis activity in a mouse model of type-II collagen-induced arthritis. , 2020, Journal of Integrative Medicine.

[4]  A. Nadeem,et al.  CXC chemokine receptor 3 antagonist AMG487 shows potent anti-arthritic effects on collagen-induced arthritis by modifying B cell inflammatory profile. , 2020, Immunology letters.

[5]  Qi Shi,et al.  Alleviation of Synovial Inflammation of Juanbi-Tang on Collagen-Induced Arthritis and TNF-Tg Mice Model , 2020, Frontiers in Pharmacology.

[6]  Kai Wang,et al.  Monocyte chemoattractant protein‑1 promotes the proliferation, migration and differentiation potential of fibroblast‑like synoviocytes via the PI3K/P38 cellular signaling pathway. , 2020, Molecular medicine reports.

[7]  A. Nadeem,et al.  CXCR3 antagonist AMG487 suppresses rheumatoid arthritis pathogenesis and progression by shifting the Th17/Treg cell balance. , 2019, Cellular signalling.

[8]  Xiaoli Yang,et al.  Germacrone alleviates collagen-induced arthritis via regulating Th1/Th2 balance and NF-κB activation. , 2019, Biochemical and biophysical research communications.

[9]  C. Zheng,et al.  Therapeutic effects of the total lignans from Vitex negundo seeds on collagen-induced arthritis in rats. , 2019, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[10]  Haiyan Zhou,et al.  Elevated circulating T cell subsets and cytokines expression in patients with rheumatoid arthritis , 2019, Clinical Rheumatology.

[11]  G. Burmester,et al.  Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference? , 2018, BioDrugs.

[12]  M. R. Shah,et al.  Rutin and rutin‐conjugated gold nanoparticles ameliorate collagen‐induced arthritis in rats through inhibition of NF‐&kgr;B and iNOS activation , 2018, International immunopharmacology.

[13]  R. Xavier,et al.  Collagen‐induced arthritis as an animal model of rheumatoid cachexia , 2018, Journal of cachexia, sarcopenia and muscle.

[14]  P. Sarzi-Puttini,et al.  TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same? , 2017, Autoimmunity reviews.

[15]  M. Karsdal,et al.  Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis , 2018, Rheumatology.

[16]  D. Fox,et al.  Synovial cellular and molecular markers in rheumatoid arthritis , 2017, Seminars in Immunopathology.

[17]  C. Hitchon,et al.  Buprenorphine Alters Inflammatory and Oxidative Stress Molecular Markers in Arthritis , 2017, Mediators of inflammation.

[18]  V. Taneja,et al.  B cells influence sex specificity of arthritis via myeloid suppressors and chemokines in humanized mice. , 2017, Clinical immunology.

[19]  T. Huizinga,et al.  Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis , 2017, Arthritis Research & Therapy.

[20]  G. Firestein,et al.  Immunopathogenesis of Rheumatoid Arthritis. , 2017, Immunity.

[21]  A. Nadeem,et al.  The tyrosine kinase inhibitor tyrphostin AG126 reduces activation of inflammatory cells and increases Foxp3+ regulatory T cells during pathogenesis of rheumatoid arthritis. , 2016, Molecular immunology.

[22]  G. Burmester,et al.  Targeting GM-CSF in rheumatoid arthritis. , 2016, Clinical and experimental rheumatology.

[23]  Jing Luo,et al.  MDM2 promotes rheumatoid arthritis via activation of MAPK and NF-κB. , 2016, International immunopharmacology.

[24]  Anil Kumar Singh,et al.  Thymoquinone inhibits TNF-α-induced inflammation and cell adhesion in rheumatoid arthritis synovial fibroblasts by ASK1 regulation. , 2015, Toxicology and applied pharmacology.

[25]  I. Wicks,et al.  Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in r , 2015, Arthritis Research & Therapy.

[26]  D. Isenberg,et al.  Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus , 2015, Arthritis & rheumatology.

[27]  D. Furst,et al.  Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. , 2014, Rheumatology.

[28]  A. Alghasham,et al.  Therapeutic targets for rheumatoid arthritis: Progress and promises , 2014, Autoimmunity.

[29]  Chee-Jen Chang,et al.  Blood Monocyte Chemotactic Protein-1 (MCP-1) and Adapted Disease Activity Score28-MCP-1: Favorable Indicators for Rheumatoid Arthritis Activity , 2013, PloS one.

[30]  권성렬.  Intra-articular nuclear factor-kB blockade ameliorates collagen-induced arthritis in mice by eliciting regulatory T cells and macrophages , 2013 .

[31]  M. Soucek,et al.  RANTES, MCP-1 chemokines and factors describing rheumatoid arthritis. , 2012, Molecular immunology.

[32]  H. L. Wright,et al.  Analysis of SF and plasma cytokines provides insights into the mechanisms of inflammatory arthritis and may predict response to therapy. , 2012, Rheumatology.

[33]  Georg Schett,et al.  The pathogenesis of rheumatoid arthritis. , 2011, The New England journal of medicine.

[34]  Bin Zhou,et al.  Administering human adipose-derived mesenchymal stem cells to prevent and treat experimental arthritis. , 2011, Clinical immunology.

[35]  R. Jeon,et al.  SPA0355, a thiourea analogue, inhibits inflammatory responses and joint destruction in fibroblast‐like synoviocytes and mice with collagen‐induced arthritis , 2011, British journal of pharmacology.

[36]  F. Magrini,et al.  Extended Report , 2011 .

[37]  Yoshihiro Baba,et al.  B cell signaling and fate decision. , 2010, Annual review of immunology.

[38]  Wei He,et al.  The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients , 2010, Rheumatology International.

[39]  M. Feldmann,et al.  Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis , 2009, Nature Reviews Rheumatology.

[40]  Y. Naito,et al.  Inhalation of Carbon Monoxide Ameliorates Collagen-induced Arthritis in Mice and Regulates the Articular Expression of IL-1β and MCP-1 , 2009, Inflammation.

[41]  B. Zheng,et al.  Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis , 2008, Proceedings of the National Academy of Sciences.

[42]  Huaxi Xu,et al.  Natural killer cell degeneration exacerbates experimental arthritis in mice via enhanced interleukin-17 production. , 2008, Arthritis and rheumatism.

[43]  Jeffrey R Curtis,et al.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[44]  P. Tak,et al.  Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. , 2008, Pharmacology & therapeutics.

[45]  E. S. St. Clair,et al.  B Cell Depletion Delays Collagen-Induced Arthritis in Mice: Arthritis Induction Requires Synergy between Humoral and Cell-Mediated Immunity1 , 2007, The Journal of Immunology.

[46]  Georg Schett,et al.  Cytokines in the pathogenesis of rheumatoid arthritis , 2007, Nature Reviews Immunology.

[47]  M. Dougados,et al.  Consensus statement on the use of rituximab in patients with rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[48]  G. Hallmans,et al.  Up regulation of monocyte chemoattractant protein-1 expression in anti-citrulline antibody and immunoglobulin M rheumatoid factor positive subjects precedes onset of inflammatory response and development of overt rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[49]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.

[50]  P. Collin‐Osdoby,et al.  RANKL Stimulates Inducible Nitric-oxide Synthase Expression and Nitric Oxide Production in Developing Osteoclasts , 2006, Journal of Biological Chemistry.

[51]  Y. Ohsugi,et al.  Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. , 2005, International immunopharmacology.

[52]  A. Filer,et al.  A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. , 2005, Arthritis and rheumatism.

[53]  G. Cheng,et al.  Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. , 2005, Cancer research.

[54]  P. Emery,et al.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.

[55]  T. Sundqvist,et al.  Inducible nitric oxide synthase is expressed in synovial fluid granulocytes , 2002, Clinical and experimental immunology.

[56]  I. Verma,et al.  NF-κB regulation in the immune system , 2002, Nature Reviews Immunology.

[57]  M. Leandro,et al.  Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion , 2002, Annals of the rheumatic diseases.

[58]  T. Kagari,et al.  The Importance of IL-1β and TNF-α, and the Noninvolvement of IL-6, in the Development of Monoclonal Antibody-Induced Arthritis , 2002, The Journal of Immunology.

[59]  H. Ishikawa,et al.  Interleukin-2 Levels are Elevated in the Bone Marrow Serum of Patients with Mutilans-Type Rheumatoid Arthritis , 2002, Clinical Rheumatology.

[60]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[61]  P. Tak,et al.  Inhibitor of nuclear factor κB kinase β is a key regulator of synovial inflammation , 2001 .

[62]  J. Hamilton,et al.  Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease , 2001, Arthritis research.

[63]  G. Panayi,et al.  Cytokine pathways and joint inflammation in rheumatoid arthritis. , 2001, The New England journal of medicine.

[64]  J. Hamilton,et al.  The colony‐stimulating factors and collagen‐induced arthritis: exacerbation of disease by M‐CSF and G‐CSF and requirement for endogenous M‐CSF , 2000, Journal of leukocyte biology.

[65]  V. Diehl,et al.  Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. , 1998, Blood.

[66]  K. Takagi,et al.  THE ROLE OF MONOCYTE CHEMOATTRACTANT PROTEIN‐1 (MCP‐1) IN THE PATHOGENESIS OF COLLAGEN‐INDUCED ARTHRITIS IN RATS , 1997, The Journal of pathology.

[67]  M. Burdick,et al.  Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. , 1994, The Journal of clinical investigation.